Absci Announces Positive Interim Phase 1 Data for ABS-201 Targeting Androgenetic Alopecia and Endometriosis
Biotechnology innovator Absci Corporation has announced encouraging interim results from its first-in-human Phase 1 clinical trial of ABS-201, a novel…
